Agilent Technologies (NYSE:A) Given New $128.00 Price Target at Evercore ISI

Key Points

• Evercore ISI has lowered its price target for Agilent Technologies from $130.00 to $128.00, maintaining an "in-line" rating that suggests a potential upside of 7.72% from the stock's previous close.
• Agilent Technologies reported $1.37 EPS for the last quarter, which met analysts' expectations, with a year-over-year revenue increase of 10.1%.
• Currently, the consensus target price for Agilent Technologies stands at $138.67, with an average rating of "Moderate Buy" from analysts, indicating a mixed outlook among research firms.

Agilent Technologies (NYSE:A - Get Free Report) had its price target cut by research analysts at Evercore ISI from $130.00 to $128.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an "in-line" rating on the medical research company's stock. Evercore ISI's price objective would suggest a potential upside of 7.72% from the stock's previous close.

Several other research analysts have also weighed in on A. JPMorgan Chase & Co. cut their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. Leerink Partners increased their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. TD Cowen lifted their price target on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Robert W. Baird dropped their price objective on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a report on Thursday, May 22nd. Finally, Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus target price of $138.67.

Agilent Technologies Stock Up 0.4%

A stock opened at $118.83 on Thursday. The company has a 50 day moving average price of $117.99 and a two-hundred day moving average price of $116.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. The stock has a market capitalization of $33.76 billion, a P/E ratio of 29.34, a PEG ratio of 3.59 and a beta of 1.22. Agilent Technologies has a one year low of $96.43 and a one year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts' consensus estimates of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The business's revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, sell-side analysts expect that Agilent Technologies will post 5.58 EPS for the current year.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Institutional Trading of Agilent Technologies

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agilent Technologies by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after purchasing an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after buying an additional 2,371 shares during the period. Alps Advisors Inc. lifted its holdings in Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after buying an additional 3,040 shares in the last quarter. D.A. Davidson & CO. boosted its position in Agilent Technologies by 30.4% in the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after buying an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. grew its stake in shares of Agilent Technologies by 7.6% during the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after acquiring an additional 54,302 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.